ReviewProceedings of the National Academy of Sciences of the United States of America1996
Facilitating oligonucleotide delivery: helping antisense deliver on its promise.
Review in Proceedings of the National Academy of Sciences of the United States of America, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Glycotargeting to improve cellular delivery efficiency of nucleic acids.Glycoconjugate journal · 2007Review
- A small inhibitor of the interaction between Bax and Bcl-X(L) can synergize with methylprednisolone to induce apoptosis in Bcl-X(L)-overexpressing breast-cancer cells.Journal of cancer research and clinical oncology · 2003Article
- A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance.Cancer gene therapy · 2003Article
- The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.Biomaterials · 2002Review
- Peptide nucleic acid delivery to human mitochondria.Gene therapy · 1999Article
- Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide.Antimicrobial agents and chemotherapy · 1999Article
- Update on metastatic breast cancer.Current oncology reports · 1999Review
- Preclinical and clinical pharmacology of antisense oligonucleotides.Molecular biotechnology · 1999Review
- Prospects for genetic intervention in primary open-angle glaucoma.Drugs & aging · 1998Review
- Real time detection of DNA.RNA hybridization in living cells.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Peptide nucleic acid-targeted mutagenesis of a chromosomal gene in mouse cells.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Shal-type channels contribute to the Ca2+-independent transient outward K+ current in rat ventricle.The Journal of physiology · 1997Article
- Accessibility of nuclear DNA to triplex-forming oligonucleotides: the integrated HIV-1 provirus as a target.Proceedings of the National Academy of Sciences of the United States of America · 1997Article
- The Use of Antisense Oligonucleotides in Evaluating Survivin as a Therapeutic Target for Radiation Sensitization in Lung Cancer.Biological procedures onlineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.